Your session is about to expire
← Back to Search
Osimertinib + Necitumumab for Lung Cancer
Study Summary
This trial studies the side effects and best dose of necitumumab when given with osimertinib in treating patients with EGFR-mutant non-small cell lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 633 Patients • NCT00982111Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any unmanaged ongoing illnesses.I have a heart condition related to abnormal heart rhythms.My heart's pumping ability is below normal.I am HIV-positive and on combination antiretroviral therapy.You are currently taking any other experimental medications.You meet certain requirements for the dose escalation and expansion groups A, B, C, D, and E.You have a specific amount of disease that can be measured using a standard method called RECIST 1.1.I have not had major surgery in the last 3 weeks.I have had lung conditions caused by drugs, disease, or radiation.You are expected to live for at least 3 more months.My lung cancer is stage IV or recurrent with specific EGFR mutations.I can provide tissue samples from after my cancer progressed on EGFR-TKI treatment.I have had previous treatments for my condition.I am 18 years old or older.I am fully active or can carry out light work.I can swallow pills.My blood, liver, and kidney functions are all within normal ranges.
- Group 1: Treatment (osimertinib, necitumumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any open slots for this experiment?
"According to clinicaltrials.gov, this medical research is not presently recruiting any participants and has been inactive since July 1st 2022. Despite the lack of openings for this trial, there are currently 3760 other trials requiring enrollment from prospective patients."
Is this an unprecedented clinical trial?
"Necitumumab has had a long research trajectory, beginning with the ICON Clinical Research-sponsored trial of 1093 participants in 2010. Since then, 102 active trials have been conducted across 1080 cities and 53 countries; 43 of these studies have since reached completion."
Has Necitumumab been previously investigated in any research?
"Since its inception at ImClone Investigational Site in 2010, necitumumb has been a subject of 43 completed clinical trails. At present time, 102 trials are actively recruiting participants; with many locations being based out of Duarte, California."
To what degree could Necitumumab endanger a patient's health?
"Since this is a Phase 1 trial, there is insufficient data to draw conclusions on Necitumumab's safety and efficacy. As such, it was given a score of 1."
How many individuals have opted to take part in this research initiative?
"This clinical trial has closed applications, initially posted on March 24th 2016 and last edited July 1st 2022. For those seeking alternative trials, 3658 are recruiting patients with metastatic lung non-small cell carcinoma and 102 for Necitumumab."
How many medical centers offer access to this trial?
"Fifteen clinics, spread between Duarte, Durham and Sacramento amongst other cities are presently running this clinical trial. It is recommended to find the nearest location in order to reduce travel strain for those who choose to join."
Share this study with friends
Copy Link
Messenger